1. Breast Cancer Drug Avastin Faces FDA Panel
... will go before the FDA's Center for Drug Evaluation and Research (CDER) to fight for the fate of the drug Avastin for breast cancer patients. In July of 2010, Avastin lost its right as a therapy to treat advanced, or metastatic, breast cancer when an advisory panel voted 12-1 to withdraw the drug. Four clinical studies concluded that the drug did not make patients live ... under, allowed for the appeal. Despite the ongoing battle, many doctors are already opting not to prescribe Avastin, according to Charlotte Arnold, a Genentech spokeswoman. Only 20-25 percent of new breast cancer pati...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate